August 24, 2011
Massachusetts sought Wednesday to intervene in a U.S. Department of Justice suit claiming Healthpoint Ltd. caused Medicaid to pay $90 million in claims for bedsore ointment Xenaderm despite its ineligibility for coverage.
April 01, 2011
The U.S. Department of Justice on Thursday accused Healthpoint Ltd. of falsely marketing the bedsore ointment Xenaderm as a prescription drug qualifying for Medicare and Medicaid reimbursement, causing the agencies to pay $90 million for an ineligible drug.